BrainStorm Cell Therapeutics Inc (BCLI)

[midastouch017]

BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit

https://finance.yahoo.com/news/brainstorm-cell-therapeutics-present-12th-120000759.html

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D., MHSc, President and Chief Medical Officer of BrainStorm Cell Therapeutics, will provide a corporate and clinical overview at the 12th Annual California ALS Research Summit, which is being held virtually January 27-28, 2022.

Dr. Kern's presentation will take place on January 27, 2022, at 4:45 p.m. ET. Those interested in registering for the summit can do so here.

About NurOwn®

The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions. NurOwn (autologous MSC-NTF cells) is designed to effectively deliver high levels of multiple neurotrophic factors (NTFs) and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.